. 2021 May 1;10(9):1054–1063. doi: 10.1002/cpdd.937

Table 4.

Statistical Analysis Results of the Effect of Dabrafenib (Initial Dosing or Steady State) on Midazolam PK Parameters

PK Parameter^a	Treatment Comparison^b	Ratio or Difference (90%CI)
AUC_0‐∞, ng • h/mL	B:A	1.00 (0.78 to 1.29)
	C:A	0.35 (0.27 to 0.45)
C_max, ng/mL	B:A	0.99 (0.81 to 1.22)
	C:A	0.53 (0.43 to 0.66)
t_max, h	B−A	−0.12 (−0.13 to 0)
	C−A	−0.13 (−0.25 to 0)

AUC, area under the concentration‐time curve; AUC_0‐∞, AUC from time 0 (predose) extrapolated to infinite time; CI, confidence interval; C_max, maximum observed concentration; PK, pharmacokinetics; t_max, time to C_max.

^{^a}

Ratio of C_max and AUC is the geometric least squares mean of test versus reference (90%CI); ratio of t_max is the median difference (90%CI).

^{^b}

Treatments A, B, and C were as follows:

(A) Single doses of rosuvastatin 10 mg + midazolam 3 mg on PK day 1.

(B) Single doses of rosuvastatin 10 mg + midazolam 3 mg + dabrafenib 150 mg twice daily at initial dosing on PK day 8.